Overview Latest Regional Industry Featured Multimedia Other Languages Public Company News
All APAC Global
All APAC Global
All APAC Global
All APAC Global
Akeso's Cadonilimab Receives Second Indication Approval from NMPA for First-Line Treatment of Gastric/GEJ Cancer in All-Comers Population 2024-09-30 13:42
Akeso's Ivonescimab plus Chemo in First-Line Triple-negative Breast Cancer Showed Promising Preliminary Efficacy and Good Safety at ESMO 2024 2024-09-16 15:35
Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 2024-09-15 15:10
Akeso to Present Data from 13 Clinical Studies at ESMO 2024, Featuring its Internally Developed Cadonilimab, Ivonescimab, Ligufalimab, and other I/O Antibodies 2024-09-06 08:54
Akeso's 2024 First Half Interim Results: Expanding Global Lead in IO Bispecific Antibodies, Advancing New Therapies, and Accelerating Commercialization 2024-08-29 04:20
Ivonescimab (PD-1/VEGF) Received Priority Review from China's NMPA for First-Line Treatment of PD-L1 Positive NSCLC 2024-08-15 07:30
First Patient Enrolled in the US Phase 2 Combination Therapy of Akeso's Ligufalimab with Azacitidine for Myelodysplastic Syndrome 2024-08-06 12:44
Akeso's sBLA for Ivonescimab in 1L Treatment of PD-L1 Positive NSCLC Accepted by NMPA 2024-07-29 17:26
Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for 2L+ EGFRm NSCLC based on HARMONi-A Clinical Trial: Positive Trend Observed in Overall Survival towards Ivonescimab Plus Chemotherapy 2024-06-01 19:10
Ivonescimab Monotherapy Decisively Beats Pembrolizumab Monotherapy Head-to-Head, Achieves Statistically Significant Superiority in PFS in First-Line Treatment of Patients with PD-L1 Positive NSCLC 2024-05-31 02:21
Oral report | The positive interim analysis results from the Phase III clinical study of Akeso's Cadonilimab (PD-1/CTLA-4 BsAb) plus chemotherapy as first-line treatment for advanced gastric cancer presented at 2024 AACR 2024-04-09 04:53
Akeso Announced the First Patient Dosed in Phase III Trial of Cadonilimab(PD-1/CTLA-4) Combined with Chemotherapy versus Tislelizumab Combined with Chemotherapy in First-line Treatment of PD-L1 negative NSCLC 2024-03-06 18:07
The promising results of a phase II clinical study for Akeso's Cadonilimab (PD-1/CTLA-4) combined standard treatment for first-line treatment of R/M cervical cancer has been published in Clinical Cancer Research 2024-02-28 17:27
Akeso Presented Promising Results of Cadonilimab and Lenvatinib in Combination with TACE in uHCC at 2024 ASCO GI 2024-01-23 21:00
Akeso to Present at the 42nd Annual J.P. Morgan Healthcare Conference and Share Its Corporate & Innovative Clinical Development Roadmap 2024-01-08 21:38
Supplemental New Drug Application for Akeso's Cadonilimab (PD-1/CTLA-4) Accepted by NMPA for First-line Treatment of Gastric Cancer 2024-01-05 21:00
Akeso Published Results from CD47 Antibody Ligufalimab in Combination with Azacitidine for Newly Diagnosed Higher-Risk Myelodysplastic Syndrome and Treatment-naïve Acute Myeloid Leukemia at ASH 2023 2023-12-15 21:00
Results of three investigator-initiated trials on cadonilimab (PD-1/CTLA-4) for G/GEJC, pMMR/MSS mCRC, and HCC neoadjuvant therapy published at ESMO Asia 2023 2023-12-05 21:00
Akeso Launches Construction of Shanghai Global R&D Center to Accelerate Its Innovation Globalization Strategy 2023-11-28 21:00
Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) Met Primary Endpoint of Progression-Free Survival in Phase III Trial for First-Line Treatment of Recurrent/Metastatic Cervical Cancer in All-Comer Patients 2023-11-27 21:30
1 2 3 4